Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.

Calcineurin inhibitors seem to be a good therapeutic option for managing ILD associated with antisynthetase autoantibodies, not only in refractory cases, but also as first-line treatment.